Generic Sorilux Availability
Last updated on Apr 10, 2025.
Sorilux is a brand name of calcipotriene topical, approved by the FDA in the following formulation(s):
SORILUX (calcipotriene - aerosol, foam;topical)
-
Manufacturer: MAYNE PHARMA
Approval date: October 6, 2010
Strength(s): 0.005% [RLD]
Is there a generic version of Sorilux available?
No. There is currently no therapeutically equivalent version of Sorilux available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sorilux. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Vitamin formulation
Patent 8,263,580
Issued: September 11, 2012
Inventor(s): Buchta Richard & Houlden Robert James & Ye Rose & Larm Maria Graziella & Loupenok Leon
Assignee(s): Stiefel Research Australia Pty LtdA pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.
Patent expiration dates:
- May 7, 2028✓✓
- May 7, 2028✓✓
- May 7, 2028
-
Vitamin formulation
Patent 8,629,128
Issued: January 14, 2014
Inventor(s): Buchta Richard & Houlden Robert James & Larm Maria Graziella & Loupenok Leon & Ye Rose
Assignee(s): Stiefel West Coast, LLCA pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use. In a second embodiment, an oil-in water emulsion having a vitamin, an occlusive agent; an aqueous solvent; and an organic cosolvent, wherein the occlusive agent is present in an amount sufficient to form an occlusive layer on the skin.
Patent expiration dates:
- May 26, 2026✓✓
- May 26, 2026✓✓
- May 26, 2026✓✓
- May 26, 2026
More about Sorilux (calcipotriene topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical antipsoriatics
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.